Abstract：Objective To investigate the clinical effect of edaravone combined with urokinase intravenous thrombolysis in the treatment of acute cerebral infarction. Methods A total of 87 patients with acute cerebral infarction admitted to Huaxian People's Hospital from February 2016 to May 2017 were randomly divided into a trial group (n=44) and a control group (n=43). The control group was treated with urokinase intravenous thrombolysis, and on this basis, the trial group was treated with edaravone, and the results of the two groups were analyzed and compared. Results There was no significant difference between the two groups before the treatment in the levels of inflammatory factors (P>0.05). After the treatment, the levels of hs-CRP and TNF-alpha in the trial group were lower than those in the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before the treatment (P>0.05). After the treatment, the NIHSS scores in the trial group were lower than those in the control group (P<0.05), and the ADL scores in the trial group were lower than those in the control group (P<0.05). The total effective rate was 93.18% in the trial group, which was higher than that (72.09%) in the control group (P<0.05). Conclusion Edaravone combined with urokinase intravenous thrombolysis is effective in the treatment of acute cerebral infarction. It can alleviate the degree of neurological deficit, alleviate inflammation and improve the ability of daily living of patients with acute cerebral infarction. It is worthy of popularizing and applying.
郭红玲. 依达拉奉联合尿激酶静脉溶栓治疗急性脑梗死的临床效果观察[J]. 中国校医, 2019, 33(11): 844-845,870.
GUO Hong-ling. Clinical effect of edaravone combined with urokinase intravenous thrombolysis in treatment of acute cerebral infarction. Chinese Journal of School Doctor, 2019, 33(11): 844-845,870.
2019, Vol. 33 
